罗沙司他，再来一个失利临床。
FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)
Study Did Not Meet Primary Endpoint.$纤维蛋白原(FGEN)$ $阿斯利康(AZN)$
| 发布于: | Android | 转发：0 | 回复：0 | 喜欢：0 |
罗沙司他，再来一个失利临床。
FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)
Study Did Not Meet Primary Endpoint.$纤维蛋白原(FGEN)$ $阿斯利康(AZN)$